US SB474 | 2019-2020 | 116th Congress

Status

Spectrum: Partisan Bill (Democrat 12-0)
Status: Introduced on February 13 2019 - 25% progression
Action: 2019-02-13 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 This bill requires manufacturers of drugs with specified percentage increases in their wholesale costs to submit to the Centers for Medicare & Medicaid Services (CMS) written justification for certain increases in drug prices. The CMS shall publish each submission, together with an easily understandable summary, on its website. Certain proprietary information may be excluded from publication, as specified by the bill. A manufacturer that does not comply with the bill's requirements shall be subject to civil monetary penalties.

Tracking Information

Register now for our free OneVote public service or GAITS Professional trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019

Sponsors


History

DateChamberAction
2019-02-13SenateRead twice and referred to the Committee on Finance.

Subjects


US Congress State Sources


Bill Comments

feedback